recent
emerg
new
public
health
threat
herein
report
fdaapprov
gold
drug
auranofin
inhibit
replic
human
cell
low
micro
molar
concentr
treatment
cell
auranofin
result
reduct
viral
rna
hour
infect
auranofin
treatment
dramat
reduc
express
cytokin
human
cell
data
indic
auranofin
could
use
drug
limit
infect
associ
lung
injuri
due
antivir
antiinflammatori
antiro
properti
auranofin
wellknown
toxic
profil
consid
safe
human
use
authorfund
right
reserv
reus
allow
without
permiss
goldbas
compound
shown
promis
activ
wide
rang
clinic
condit
microorgan
infect
auranofin
goldcontain
triethyl
phosphin
fdaapprov
drug
treatment
rheumatoid
arthriti
sinc
investig
potenti
therapeut
applic
number
diseas
includ
cancer
neurodegen
disord
hivaid
parasit
infect
bacteri
infect
recent
auranofin
approv
fda
phase
ii
clinic
trial
cancer
therapi
mechan
action
auranofin
involv
inhibit
redox
enzym
thioredoxin
reductas
induct
endoplasm
reticulum
er
stress
subsequ
activ
unfold
protein
respons
upr
inhibit
redox
enzym
lead
cellular
oxid
stress
intrins
apoptosi
addit
auranofin
antiinflammatori
drug
reduc
cytokin
product
stimul
cellmedi
immun
dual
inhibit
inflammatori
pathway
thiol
redox
enzym
auranofin
make
attract
candid
cancer
therapi
treat
microbi
infect
coronavirus
famili
envelop
virus
posit
sens
singlestrand
rna
genom
caus
agent
close
relat
sever
acut
respiratori
syndrom
coronaviru
known
er
stress
upr
activ
contribut
significantli
viral
replic
pathogenesi
coronaviru
infect
infect
increas
express
er
protein
fold
chaperon
er
stress
relat
gene
maintain
protein
fold
cell
overexpress
sarscov
spike
protein
viral
protein
exhibit
high
level
upr
activ
thu
inhibit
redox
enzym
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
thioredoxin
reductas
induct
er
stress
auranofin
could
significantli
affect
protein
synthesi
addit
infect
caus
acut
inflamm
neutrophilia
lead
cytokin
storm
express
tnfalpha
monocyt
chemoattract
protein
reactiv
oxygen
speci
ro
sever
ill
repres
devast
inflammatori
lung
disord
due
cytokin
storm
associ
multipl
organ
dysfunct
lead
high
mortal
taken
togeth
studi
suggest
auranofin
could
mitig
infect
associ
lung
damag
due
antivir
antiinflammatori
antiro
properti
auranofin
wellknown
toxic
profil
consid
safe
human
use
investig
antivir
activ
auranofin
effect
virusinduc
inflamm
human
cell
infect
cell
multipl
infect
moi
hour
follow
addit
auranofin
dmso
use
control
solvent
use
prepar
drug
stock
cell
cultur
supernat
cell
lysat
collect
hour
infect
viru
rna
copi
measur
rtpcr
use
two
separ
primer
specif
viral
gene
gene
depict
figur
treatment
cell
auranofin
result
reduct
viral
rna
supernat
compar
dmso
hour
infect
hour
reduct
viral
rna
supernat
compar
dmso
similarli
level
intracellular
viral
rna
decreas
hour
hour
auranofintr
cell
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
compar
dmsotreat
cell
set
primer
show
nearli
ident
result
auranofin
show
toxic
cell
use
concentr
hour
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
taken
togeth
result
demonstr
auranofin
inhibit
replic
human
cell
low
micro
molar
concentr
also
demonstr
auranofin
treatment
result
signific
reduct
virusinduc
inflamm
data
indic
auranofin
could
use
drug
limit
infect
associ
lung
injuri
anim
studi
warrant
evalu
efficaci
auranofin
manag
associ
diseas
studi
use
novel
isol
oropharyng
swab
patient
washington
usa
bei
viru
strain
amplifi
vero
cell
titer
x
plaqueform
unit
pfu
ml
cell
human
liver
cell
line
grown
dmem
gibco
supplement
heatinactiv
fetal
bovin
serum
cell
infect
pb
mock
multipl
infect
moi
hour
cell
wash
twice
pb
media
contain
differ
concentr
auranofin
sigma
dmso
sigma
ad
cell
supernat
cell
lysat
harvest
hour
infect
viru
rna
level
analyz
supernat
cell
lysat
quantit
revers
transcriptionpolymeras
chain
reaction
qrtpcr
rna
cell
cultur
supernat
extract
use
viral
rna
mini
kit
qiagen
rna
cell
lysat
extract
use
rneasi
mini
kit
qiagen
describ
previous
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
qrtpcr
use
measur
viral
rna
level
use
previous
publish
primer
probe
specif
forward
revers
mrna
analysi
nfkb
cdna
prepar
rna
isol
cell
lysat
use
cdna
synthesi
kit
biorad
hercul
ca
usa
qrtpcr
conduct
describ
previous
primer
sequenc
use
qrtpcr
list
tabl
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
